Patrick Boland, MD
Hematology & Oncology · Westbrook, MENPI 1083140883
Payments from drug & device makers
Across 79 payments — averaging $252.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pharmacosmos Therapeutics Inc.$9K
- Avyxa Pharma, LLC$3K
- Pfizer$3K
- Beigene USA, Inc.$775
- Genmab U.S., Inc.$764
- Daiichi Sankyo Inc.$698
- plus $2K from 22 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pharmacosmos Therapeutics Inc. | 7 | $9,205 |
| Avyxa Pharma, LLC | 4 | $3,279 |
| Pfizer | 7 | $2,871 |
| Beigene USA, Inc. | 2 | $775 |
| Genmab U.S., Inc. | 6 | $764 |
| Daiichi Sankyo Inc. | 4 | $698 |
| AstraZeneca | 6 | $535 |
| AbbVie | 12 | $515 |
| Sobi, Inc | 1 | $200 |
| GSK | 3 | $180 |
| Adaptive Biotechnologies Corporation | 2 | $163 |
| ADC Therapeutics America, Inc. | 4 | $155 |
| Genentech USA, Inc. | 1 | $150 |
| Syndax Pharmaceuticals, Inc. | 4 | $105 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $73 |
| Stemline Therapeutics Inc. | 2 | $43 |
| Johnson & Johnson | 1 | $34 |
| Aimmune Therapeutics, Inc. | 1 | $30 |
| Caris MPI, Inc. | 1 | $28 |
| Astellas Pharma US Inc | 1 | $23 |
| Merck | 1 | $21 |
| Rigel Pharmaceuticals, Inc. | 1 | $20 |
| Progenics Pharmaceuticals, Inc. | 1 | $18 |
| Coherus Oncology, Inc. | 1 | $18 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $15 |
| Eisai Inc. | 1 | $14 |
| Novocure Inc. | 1 | $14 |
| Gilead | 1 | $13 |
How this compares
$19,959 in reported general payments places this provider in the 70th percentile of 60 hematology & oncology providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Westbrook
- Christian ThomasWestbrook$4.7M
- Chiara BattelliWestbrook$1.5M
- Matthew DuganWestbrook$675K
- John WintersWestbrook$341K
- Devon EvansWestbrook$248K
- Eleni NackosWestbrook$217K
- Tracey WeisbergWestbrook$109K
- Daniel RauschWestbrook$104K
- Owen PickusWestbrook$1K
- Anna NiegowskaPortland$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.